榴莲视频

This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.

This randomized clinical trial assesses the safety and effectiveness of plozasiran, an investigational APOC3-targeted drug, in the reduction of serum triglyceride level in patients with severe hypertriglyceridemia.

This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)鈥揑nhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovascular disease.

This randomized clinical trial compares a single dose of lepodisiran vs placebo to assess the safety, tolerability, pharmacokinetics, and effects on lipoprotein(a) concentrations in adults without cardiovascular disease and with lipoprotein(a) serum concentrations of 75 nmol/L or greater at baseline.

This phase 1 randomized clinical trial evaluates the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarker effects of muvalaplin in humans.

This 32-country randomized clinical trial assesses the effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients receiving bempedoic acid vs placebo for primary prevention of a first major adverse cardiovascular event.

This secondary analysis of a randomized clinical trial investigates the association between plasma levels of eicosapentaenoic acid and docosahexaenoic acid and cardiovascular outcomes in a trial of 蠅-3 fatty acids compared with corn oil placebo.

This randomized trial examines the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.

This secondary analysis of the randomized clinical ACCELERATE trial examines whether lipoprotein(a)-associated cardiovascular risk is modulated by systemic inflammation in optimally treated patients at high risk for cardiovascular disease.

This randomized trial compares the effects of apabetalone (an inhibitor of bromodomain 2 and extraterminal protein, 2 epigenetic 鈥渞eaders鈥�) vs placebo on major adverse cardiovascular events in patients with acute coronary syndrome (ACS), type 2 diabetes, and low HDL cholesterol level.

This genetic epidemiology study uses UK Biobank database data to estimate the association between genetic variants associated with lower low-density lipoprotein cholesterol (LDL-C), lower systolic blood pressure (SBP), or both and cardiovascular disease (CVD), defined as coronary death, nonfatal, myocardial infarction, or coronary revascularization.

This study examines the association of intraindividual blood pressure variability, coronary atheroma progression, and clinical outcomes using serial intravascular ultrasonography.

This secondary analysis of a randomized clinical trial examines whether longitudinal increases in high-sensitivity C-reactive protein levels during 16 weeks after an acute coronary syndrome are associated with increased risk of a major adverse cardiac event, cardiovascular death, and all-cause death.

This mendelian randomization analysis compares the association of triglyceride-lowering variants in the lipoprotein lipase (LPL) gene and of LDL-C鈥搇owering variants in the LDL receptor gene (LDLR) with coronary heart disease (CHD) risk per unit change in apolipoprotein B.

This randomized clinical trial determines the effect of an intravenous infusion of CER-001 on coronary atherosclerosis progression in statin-treated patients.